← Back to Search

Cannabinoid

Cannabidiol (CBD) for Radiculopathy

Phase 1 & 2
Waitlist Available
Led By Stephen Ross, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 post-initiation of treatment, week 2 post-initiation of treatment

Summary

This trial is testing whether taking 600mg of CBD daily can help reduce pain in people with chronic spinal nerve pain who are already on stable opioid medications. The study will last for a short period, and researchers will compare the effects of CBD to see if it is safe and effective.

Eligible Conditions
  • Radiculopathy
  • Spinal Radiculopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 post-initiation of treatment, week 2 post-initiation of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 post-initiation of treatment, week 2 post-initiation of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in CBD Plasma Levels
Change in Opioid Analgesic Plasma Levels
Secondary study objectives
Pain
Change in Score on Pain Catastrophizing Scale (PCS)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Cannabidiol (CBD)Active Control1 Intervention
Group II: Placebo (PCB)Placebo Group1 Intervention

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,410 Previous Clinical Trials
855,592 Total Patients Enrolled
1 Trials studying Radiculopathy
120 Patients Enrolled for Radiculopathy
National Institute on Drug Abuse (NIDA)NIH
2,589 Previous Clinical Trials
3,328,503 Total Patients Enrolled
Stephen Ross, MDPrincipal InvestigatorNYU Langone Health
5 Previous Clinical Trials
426 Total Patients Enrolled

Media Library

Cannabidiol (Cannabinoid) Clinical Trial Eligibility Overview. Trial Name: NCT04760613 — Phase 1 & 2
Radiculopathy Research Study Groups: Cannabidiol (CBD), Placebo (PCB)
Radiculopathy Clinical Trial 2023: Cannabidiol Highlights & Side Effects. Trial Name: NCT04760613 — Phase 1 & 2
Cannabidiol (Cannabinoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04760613 — Phase 1 & 2
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top